Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients

Kaplan M., Yavuz F., Kaplan G. I. , BURSA N., VURUŞKAN E., Sucu M.

ANATOLIAN JOURNAL OF CARDIOLOGY, vol.25, no.5, pp.330-337, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.14744/anatoljcardiol.2020.17329
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.330-337
  • Hacettepe University Affiliated: Yes


Objective: Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD.